| Description | Etrolizumab (rhuMAb Beta7), a gut-selective anti-β7 integrin monoclonal antibody, targets the β7 subunit of α4β7 and αEβ7 integrins specifically, demonstrating affinity with K i values of 18 nM for Human α4β7 and 1800 pM for Human αEβ7-293. It is utilized in the research of inflammatory bowel disease (IBD) [1] [2]. |
| molecular weight | N/A |
| CAS | 1044758-60-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years |